Mediconix provides professional services to pharmaceutical, biotechnology and medical industry clients giving assistance with the development and launching of their products in the Czech and Slovak Republic.
Mediconix assists to clinical research institutions and hospitals providing significant expertise in conducting clinical trials in order to bring safe and effective treatment to the involved patients.
Boehringer Ingelheim affirms safety of telmisartan with an analysis of 50,000 patients
11.10.2011
Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients.
MoreRoACTEMRA: New hope for children with systemic Juvenile Idiopathic Arthritis
22.06.2010
Roche announced that new data demonstrates that RoACTEMRA is highly effective in improving the signs and symptoms of systemic Juvenile Idiopathic Arthritis (sJIA)
More